This Week’s Biopharma News: Big Moves in Bispecifics - Poll - MDSpire

This Week’s Biopharma News: Big Moves in Bispecifics

Akeso’s PD-1/VEGF bispecific beats PD-1 plus chemo in lung cancer, Amgen wins EC approval for its DLL3-targeted T-cell engager, and Aragen scales Renaissance’s Fast Track anti-GD2 antibody

  • June 9, 2026

  • 5 min

Share

Original Source(s)

This Week’s Biopharma News: Big Moves in Bispecifics

  • June 9, 2026

Related Content

The Secrets of the Gut

Going beyond the gut: why microbiome testing is the next big thing in drug development

Dana-Farber Research Supports FDA Approval of New First-Line Therapy for Metastatic Triple-Negative Breast Cancer

The U.S. Food and Drug Administration (FDA) has approved the antibody-drug conjugate sacituzumab govitecan for first-line treatment of metastatic triple-negative breast cancer.

  • by

  • June 24, 2026

  • 4 min
Mass Spec Roundup: Signals Recovered

This week’s stories span amino-metabolite imaging, site-specific HDX-MS, large-scale motif annotation, and proteomics missing-value recovery

  • July 15, 2026

  • 7 min